The Journal of Phytopharmacology, 2018;7(2):216-221 DOI:10.31254/phyto.2018.7220
Pharmacovigilence practice for safety of medication system in India
Shobharam Sahu1 , Poonam Rishishwar2 , Chhaya Rathod3
1. Research Scholar, Faculty of Pharmaceutical Science, Sri Venkateshwara University, Gajraula, Uttar Pradesh, India
2. Faculty of Pharmaceutical Science, Sri Venkateshwara University, Gajraula, Uttar Pradesh, India
3. Rajiv Gandhi college of Pharmacy, Nautanwa, Maharajganj, Uttar Pradesh, India
*Author to whom correspondence should be addressed.
Received: 21st March, 2018 / Accepted: 5th April, 2018
Pharmacovigilance is very essential tool to ensure the safety of drug. It provides safety to patients in case of medication. Activity of pharmacovigilance is coordinates by National pharmacovigilance center in collaboration with international regulatory authorities (WHO, The Uppsala Monitoring center). Under the aegis of Ministry of Health & Family Welfare, Government of India, the Central Drugs Standard Control Organisation (CDSCO), New Delhi, has initiated a nation-wide pharmacovigilance programme, with the All India Institute of Medical Sciences (AIIMS), New Delhi as the National Coordinating Centre (NCC) for monitoring Adverse Drug Reactions (ADR).
Pharmacovigilance, India, Uppsala monitoring center, Drug sefty, Adverse drug reaction reporting, CDSCO, NCC, ICSR.
HOW TO CITE THIS ARTICLE
Sahu S, Rishishwar P, Rathod C. Pharmacovigilence practice for safety of medication system in India. J Phytopharmacol 2018; 7(2):216-221.
Creative Commons (CC) License-
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (http://creativecommons.org/licenses/by/4.0/).
Copyright
Copyright © 2018 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.